Abstract
Objective: To provide the first update on drug safety profiles and adverse drug reactions (ADRs) associated with fetal disorders from the Swiss national ADR database.
Methods: We conducted a retrospective study using data from 202 pharmacovigilance reports on drug-associated fetal disorders from the Swiss national ADR database from 1990 to 2009. Evaluated aspects included administrative information on the report, drug exposure, and disorders.
Results: The ADR reporting frequency on the topic of fetal disorders has increased during the last 20 years, from only 1 report in 1991 to a maximum of 31 reports in 2008. Nervous system drugs were the most frequently reported drug group (40.2%) above all antidepressants and antiepileptics. The highest level of overall drug intake could be observed for the 1st trimester (85.4%), especially for the first 6 weeks of pregnancy. The most frequently reported types of fetal disorders were malformations (68.8%), especially those of the musculoskeletal and circulatory systems. A positive association was discovered between antiepileptics and malformations in general and in particular of the circulatory system and the eye, ear, face, and neck.
Conclusions: The results suggest that the nervous system drug group bears an especially high risk for malformations. The most commonly identified drug exposures can help focus pharmacoepidemiologic efforts in drug-induced birth defects.
The authors stated that there are no confl icts of interest regarding the publication of this article.
We thank Rudolf Stoller and Rosemarie Sift Carter from the Swiss Agency for Therapeutic Products Swissmedic, Berne, Switzerland, for their support.
References
[1] Andrade SE, Raebel MA, Morse AN, Davis RL, Chan KA, Finkelstein JA, et al. Use of prescription medications with a potential for fetal harm among pregnant women. Pharmacoepidemiol Drug Saf. 2006;15:546–54.10.1002/pds.1235Search in Google Scholar
[2] Bakker MK, Jentink J, Vroom F, Van Den Berg PB, De Walle HE, De Jong-Van Den Berg LT. Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in the Netherlands. Br J Obstet Gynaecol. 2006;113:559–68.10.1111/j.1471-0528.2006.00927.xSearch in Google Scholar
[3] Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006;354:579–87.10.1056/NEJMoa052744Search in Google Scholar
[4] Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006;54:2443–51.10.1056/NEJMoa055202Search in Google Scholar
[5] Council for International Organisations of Medical Sciences. Current challenges in pharmacovigilance: pragmatic approaches. Report of CIOMS Working Group V. Geneva: CIOMS; 2001.Search in Google Scholar
[6] Egen-Lappe V, Hasford J. Drug prescription in pregnancy: analysis of a large statutory sickness fund population. Eur J Clin Pharmacol. 2004;60:659–66.10.1007/s00228-004-0817-1Search in Google Scholar
[7] Engeland A, Bramness JG, Daltveit AK, Rønning M, Skurtveit S, Furu K. Prescription drug use among fathers and mothers before and during pregnancy: a population-based cohort study of 106,000 pregnancies in Norway 2004–2006. Br J Clin Pharmacol. 2008;65:653–60.10.1111/j.1365-2125.2008.03102.xSearch in Google Scholar
[8] EUROCAT European surveillance of congenital anomalies [homepage on the Internet]. Prevalence data tables. Available from: http://www.eurocat-network.eu/accessprevalencedata/prevalencetables. Accessed February 19, 2010.Search in Google Scholar
[9] Fehlbildungsmonitoring Sachsen-Anhalt [homepage on the Internet]. Jahresbericht des Bundeslandes Sachsen-Anhalt zur Häufigkeit von congenitalen Fehlbildungen und Anomalien sowie genetisch bedingten Erkrankungen. Sachsen-Anhalt; 2008. Available from: www.angeborene-fehlbildungen.com. Accessed April 27, 2012.Search in Google Scholar
[10] Hardy JR, Leaderer BP, Holford TR, Hall GC, Bracken MB. Safety of medications prescribed before and during early pregnancy in a cohort of 81,975 mothers from the UK general practice research database. Pharmacoepidemiol Drug Saf. 2006;15:555–64.10.1002/pds.1269Search in Google Scholar
[11] Hernandez-Diaz S. Prescription of medications during pregnancy: accidents, compromises, and uncertainties. Pharmacoepidemiol Drug Saf. 2006;15:613–7.10.1002/pds.1308Search in Google Scholar
[12] Holmes LB, Harvey EA, Coull BA, Huntington KB, Khoshbin S, Hayes AM, et al. The teratogenicity of anticonvulsant drugs. N Engl J Med. 2001;344:1132–8.10.1056/NEJM200104123441504Search in Google Scholar
[13] ICH International Conference on Harmonisation [homepage on the Internet]. Efficacy guidelines: clinical safety E2A, E2B, E2C, E2D and E2E. Available from: http://www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines.html. Accessed April 27, 2012.Search in Google Scholar
[14] Lacroix I, Damase-Michel C, Lapeye-Mestre M, Montastruc JL. Prescription of drugs during pregnancy in France. Lancet. 2000;356:1735–6.10.1016/S0140-6736(00)03209-8Search in Google Scholar
[15] Lacroix I, Hurault C, Sarramon MF, Guitard C, Berrebi A, Grau M, et al. Prescription of drugs during pregnancy: a study using the EFEMERIS, the new French database. Eur J Clin Pharmacol. 2009;65:839–46.10.1007/s00228-009-0647-2Search in Google Scholar
[16] Malm H, Martikainen J, Klaukka T, Neuvonen PJ. Prescription drugs during pregnancy and lactation – a Finnish register-based study. Eur J Clin Pharmacol. 2003;59:127–33.10.1007/s00228-003-0584-4Search in Google Scholar
[17] NAAPR North American Antiepileptic Drug Pregnancy Registry [homepage on the Internet]. Newsletter. Winter 2010 issue. Available from: www.aedpregnancyregistry.org.Search in Google Scholar
[18] Perucca E. Birth defects after prenatal exposure to antiepileptic drugs. Lancet Neurol. 2005;4:781–6.10.1016/S1474-4422(05)70224-6Search in Google Scholar
[19] Schaefer C. SSRI: Embryo- und Fetotoxizität. In: SAPP Schweizerische Arbeitsgemeinschaft für Perinatale Pharmakologie. Abstractbook Jahrestagung; 2009. Available from: www.sappinfo.ch. Accessed April 27, 2012.Search in Google Scholar
[20] Schardein JL. Chemically induced birth defects. 3rd ed. New York: Marcel Dekker; 2000.10.3109/9780203909904Search in Google Scholar
[21] The Uppsala Monitoring Centre [homepage on the Internet]. The WHO adverse reaction terminology – WHO-ART. Available from: http://www.umc-products.com/graphics/3149.pdf. Accessed April 27, 2012.Search in Google Scholar
[22] The Uppsala Monitoring Centre [homepage on the Internet]. WHO Drug Dictionary. Available from: http://www.who-umc.org/DynPage.aspx?id=98105&mn1=7347&mn2=7252&mn3=7254&mn4=7338. Accessed April 27, 2012.Search in Google Scholar
[23] The World Health Organizatin [homepage on the Internet]. International Classification of Diseases (ICD). Available from: http://www.who.int/classifications/icd/en/. Accessed April 27, 2012.Search in Google Scholar
[24] Thomson T, Battino D. The management of epilepsy in pregnancy. In: Shorvon S, Pedley TA, editors. The epilepsies 3. Vol. 33. Philadelphia: Saunders Elsevier; 2009.Search in Google Scholar
[25] WHO Collaborating Centre for International Drug Monitoring. Viewpoint Part 2, watching for safer medicines [document on the Internet]. 2004. Available from: http://www.who-umc.org/graphics/24746.pdf. Accessed April 27, 2012.Search in Google Scholar
[26] Wyszynski DF, Nambisan M, Surve T, Alsdorf RM, Smith CR, Holmes LB. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology. 2005;64:961–5.10.1212/01.WNL.0000154516.43630.C5Search in Google Scholar PubMed
©2013 by Walter de Gruyter Berlin Boston
